HN2011002095A - [1,2,4] triazolo [1,5-a] pridinas como inhibidores de cinasa. - Google Patents

[1,2,4] triazolo [1,5-a] pridinas como inhibidores de cinasa.

Info

Publication number
HN2011002095A
HN2011002095A HN2011002095A HN2011002095A HN2011002095A HN 2011002095 A HN2011002095 A HN 2011002095A HN 2011002095 A HN2011002095 A HN 2011002095A HN 2011002095 A HN2011002095 A HN 2011002095A HN 2011002095 A HN2011002095 A HN 2011002095A
Authority
HN
Honduras
Prior art keywords
methods
kinase inhibitors
pridins
triazolo
compounds
Prior art date
Application number
HN2011002095A
Other languages
English (en)
Spanish (es)
Inventor
Caroline Leriche
Eric Auclair
Roux Jacques Le
David N Middlemiss
Original Assignee
Fovea Pharmaceuticals
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=42229029&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=HN2011002095(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Fovea Pharmaceuticals filed Critical Fovea Pharmaceuticals
Publication of HN2011002095A publication Critical patent/HN2011002095A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/437—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a five-membered ring having nitrogen as a ring hetero atom, e.g. indolizine, beta-carboline
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Diabetes (AREA)
  • Immunology (AREA)
  • Emergency Medicine (AREA)
  • Endocrinology (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Ophthalmology & Optometry (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
HN2011002095A 2009-02-13 2011-07-29 [1,2,4] triazolo [1,5-a] pridinas como inhibidores de cinasa. HN2011002095A (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
EP09360013 2009-02-13

Publications (1)

Publication Number Publication Date
HN2011002095A true HN2011002095A (es) 2014-01-06

Family

ID=42229029

Family Applications (1)

Application Number Title Priority Date Filing Date
HN2011002095A HN2011002095A (es) 2009-02-13 2011-07-29 [1,2,4] triazolo [1,5-a] pridinas como inhibidores de cinasa.

Country Status (24)

Country Link
US (1) US20120041195A1 (https=)
EP (1) EP2396324A1 (https=)
JP (1) JP2012517971A (https=)
KR (1) KR20110116160A (https=)
CN (1) CN102317288A (https=)
AR (1) AR075411A1 (https=)
BR (1) BRPI1008850A2 (https=)
CA (1) CA2751517A1 (https=)
CL (1) CL2011001947A1 (https=)
CO (1) CO6420343A2 (https=)
CR (1) CR20110386A (https=)
DO (1) DOP2011000248A (https=)
EA (1) EA201101188A1 (https=)
EC (1) ECSP11011250A (https=)
HN (1) HN2011002095A (https=)
IL (1) IL214426A0 (https=)
MX (1) MX2011008549A (https=)
NI (1) NI201100151A (https=)
NZ (1) NZ594508A (https=)
PE (1) PE20120110A1 (https=)
SG (1) SG173610A1 (https=)
TN (1) TN2011000379A1 (https=)
WO (1) WO2010092041A1 (https=)
ZA (1) ZA201105896B (https=)

Families Citing this family (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN102459258B (zh) * 2009-06-05 2015-11-25 赛福伦公司 1,2,4-三唑并[1,5a]吡啶衍生物的制备和用途
EP2343294A1 (en) 2009-11-30 2011-07-13 Bayer Schering Pharma AG Substituted triazolopyridines
EP2343297A1 (en) * 2009-11-30 2011-07-13 Bayer Schering Pharma AG Triazolopyridines
EP2343295A1 (en) * 2009-11-30 2011-07-13 Bayer Schering Pharma AG Triazolopyridine derivates
UY33452A (es) * 2010-06-16 2012-01-31 Bayer Schering Pharma Ag Triazolopiridinas sustituidas
AR081960A1 (es) * 2010-06-22 2012-10-31 Fovea Pharmaceuticals Sa Compuestos heterociclicos, su preparacion y su aplicacion terapeutica
HRP20150517T1 (hr) * 2011-04-21 2015-06-19 Bayer Intellectual Property Gmbh Triazolopiridini
WO2012160029A1 (en) 2011-05-23 2012-11-29 Bayer Intellectual Property Gmbh Substituted triazolopyridines
UA112096C2 (uk) 2011-12-12 2016-07-25 Байєр Інтеллектуал Проперті Гмбх Заміщені триазолопіридини та їх застосування як інгібіторів ttk
KR20130091464A (ko) 2012-02-08 2013-08-19 한미약품 주식회사 타이로신 카이네이즈 억제 활성을 갖는 트리아졸로피리딘 유도체
CN104284896B (zh) 2012-03-14 2016-06-01 拜耳知识产权有限责任公司 取代的咪唑并哒嗪
CA2878481A1 (en) 2012-07-10 2014-01-16 Bayer Pharma Aktiengesellschaft Method for preparing substituted triazolopyridines
WO2014020043A1 (en) 2012-08-02 2014-02-06 Bayer Pharma Aktiengesellschaft Combinations for the treatment of cancer
RS56034B1 (sr) 2013-06-11 2017-09-29 Bayer Pharma AG Derivati prolekova supstituisanih triazolopiridina
AU2020385513A1 (en) * 2019-11-22 2022-07-14 Medshine Discovery Inc. Pyrimidopyrrole spiro compounds and derivatives thereof as DNA-PK inhibitors

Family Cites Families (30)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS6056684B2 (ja) 1977-11-07 1985-12-11 東興薬品工業株式会社 点眼剤
US4271143A (en) 1978-01-25 1981-06-02 Alcon Laboratories, Inc. Sustained release ophthalmic drug dosage
US4407792A (en) 1979-05-09 1983-10-04 Alcon Laboratories, Inc. Sustained release ophthalmic drug dosage
AU565354B2 (en) 1983-11-14 1987-09-10 Bio-Mimetics Inc. Bioadhesive compositions and methods of treatment therewith
US5041434A (en) 1991-08-17 1991-08-20 Virginia Lubkin Drugs for topical application of sex steroids in the treatment of dry eye syndrome, and methods of preparation and application
CA2386955A1 (en) 1999-11-22 2001-05-31 Warner-Lambert Company Quinazolines and their use for inhibiting cyclin-dependent kinase enzymes
WO2004058769A2 (en) * 2002-12-18 2004-07-15 Vertex Pharmaceuticals Incorporated Triazolopyridazines as protein kinases inhibitors
EP1590341B1 (en) 2003-01-17 2009-06-17 Warner-Lambert Company LLC 2-aminopyridine substituted heterocycles as inhibitors of cellular proliferation
CN1897950A (zh) * 2003-10-14 2007-01-17 惠氏公司 稠合芳基和杂芳基衍生物及其使用方法
CN1882345A (zh) 2003-10-16 2006-12-20 希龙公司 作为raf激酶抑制剂以治疗癌症的2,6－二取代的喹唑啉、喹喔啉、喹啉和异喹啉
KR20070011458A (ko) 2004-04-08 2007-01-24 탈자진 인코포레이티드 키나제의 벤조트리아진 억제제
PL382308A1 (pl) 2004-08-25 2007-08-20 Targegen, Inc. Związki heterocykliczne i sposoby stosowania
US20070054916A1 (en) 2004-10-01 2007-03-08 Amgen Inc. Aryl nitrogen-containing bicyclic compounds and methods of use
US20060247250A1 (en) 2005-03-16 2006-11-02 Targegen, Inc. Pyrimidine inhibitors of kinases
JP5079500B2 (ja) 2005-04-28 2012-11-21 協和発酵キリン株式会社 ２−アミノキナゾリン誘導体
NZ563984A (en) 2005-06-08 2011-11-25 Targegen Inc Methods and compositions for the treatment of ocular disorders
WO2007067537A1 (en) * 2005-12-07 2007-06-14 Osi Pharmaceuticals, Inc. Pyrrolopyridine kinase inhibiting compounds
PE20070978A1 (es) 2006-02-14 2007-11-15 Novartis Ag COMPUESTOS HETEROCICLICOS COMO INHIBIDORES DE FOSFATIDILINOSITOL 3-QUINASAS (PI3Ks)
JP5336375B2 (ja) * 2006-08-30 2013-11-06 セルゾーム リミテッド キナーゼ阻害剤としてのトリアゾール誘導体
EA200900573A1 (ru) * 2006-10-20 2009-10-30 АйАрЭм ЭлЭлСи Композиции и способы для модуляции рецепторов c-kit и pdgfr
TW200829566A (en) 2006-12-08 2008-07-16 Astrazeneca Ab Chemical compounds
CA2673003A1 (en) 2006-12-22 2008-07-03 Novartis Ag Quinazolines for pdk1 inhibition
GB0719803D0 (en) * 2007-10-10 2007-11-21 Cancer Rec Tech Ltd Therapeutic compounds and their use
EP2288260A4 (en) * 2008-06-20 2013-10-23 Genentech Inc TRIAZOLOPYRIDINE-JAK HEMMER COMPOUNDS AND METHOD
BRPI0909945A2 (pt) * 2008-06-20 2015-07-28 Genentech Inc "composto, composição farmacêutica, método para tratar ou atenuar a gravidade de uma doença ou condição responsiva à inibição da atividade jak2 quinase em um paciente, kit para o tratamento de uma doença ou distúrbio responsivo à inibição da jak quinase"
WO2010010188A1 (en) * 2008-07-25 2010-01-28 Galapagos Nv Novel compounds useful for the treatment of degenerative and inflammatory diseases.
WO2010010189A1 (en) * 2008-07-25 2010-01-28 Galapagos Nv Novel compounds useful for the treatment of degenerative and inflammatory diseases
WO2010010184A1 (en) * 2008-07-25 2010-01-28 Galapagos Nv [1, 2, 4] triazolo [1, 5-a] pyridines as jak inhibitors
TW201010977A (en) * 2008-08-12 2010-03-16 Takeda Pharmaceutical Amide compound
TWI453207B (zh) * 2008-09-08 2014-09-21 Signal Pharm Llc 胺基三唑并吡啶，其組合物及使用其之治療方法

Also Published As

Publication number Publication date
CO6420343A2 (es) 2012-04-16
US20120041195A1 (en) 2012-02-16
NZ594508A (en) 2013-12-20
CL2011001947A1 (es) 2012-03-16
CA2751517A1 (en) 2010-08-19
DOP2011000248A (es) 2011-10-31
ZA201105896B (en) 2012-03-28
WO2010092041A1 (en) 2010-08-19
MX2011008549A (es) 2011-12-06
ECSP11011250A (es) 2011-10-31
BRPI1008850A2 (pt) 2016-03-15
IL214426A0 (en) 2011-09-27
SG173610A1 (en) 2011-09-29
TN2011000379A1 (en) 2013-03-27
EP2396324A1 (en) 2011-12-21
CR20110386A (es) 2011-12-02
EA201101188A1 (ru) 2012-04-30
NI201100151A (es) 2012-10-03
JP2012517971A (ja) 2012-08-09
AR075411A1 (es) 2011-03-30
CN102317288A (zh) 2012-01-11
PE20120110A1 (es) 2012-02-20
KR20110116160A (ko) 2011-10-25

Similar Documents

Publication Publication Date Title
HN2011002095A (es) [1,2,4] triazolo [1,5-a] pridinas como inhibidores de cinasa.
DK3418281T3 (da) Pyrazolo[1,5-a]pyrimidiner, der er anvendelige som inhibitorer af atr-kinase til behandling af cancersygdomme
MX370814B (es) Pirazolo[3,4-d]pirimidinas sustituidas y usos de las mismas.
CO6940433A2 (es) Compuestos inhibidores de metaloenzimas
CR20130464A (es) Inhibidores sustituidos de acetil-coa carboxilasa
EA201171367A1 (ru) Винилиндазолильные соединения
EA201300810A1 (ru) Противораковая терапия с использованием двойных ингибиторов киназ аврора/мек
UY37018A (es) Inhibidores bicíclicos de pad4
UY34352A (es) 3-pirimidin-4-il-oxazolidin-2-onas como inhibidores de la idh mutante
WO2008124849A3 (en) Pyrrolo-pyridine kinase modulators
ECSP14013152A (es) Compuestos inhibidores de metaloenzimas
MX386224B (es) Activadores de cinasa de piruvato para su uso en terapia.
CU24396B1 (es) Acrilamidas de pirrolo[2,3-d]pirimidinilo, pirrolo[2,3-b]pirazinilo y pirrolo[2,3-d]piridinilo
CR10995A (es) Inhibidores de la actividad de akt
JOP20140141B1 (ar) استخدام 3،2- ثنائي هيدروإيميدازول-[2،1-c] كونازولينات مستبدلة لمعالجة الاورام الليمفاوية
PH12013502622A1 (en) Metalloenzyme inhibitor compounds
CR20110368A (es) Compuestos de quinazolina sustituidos
MY162950A (en) Compounds and methods for kinase modulation, and indications therefor
UY33931A (es) Agentes de union biespecificos
MX2010002732A (es) Inhibidores de f1f0-atpasa y metodos relacionados.
UY32291A (es) Inhibidores de quinasa con perfiles de seguridad cyp mejorados
PT2928477T (pt) Utilização do inibidor da telomerase imetelstat para o tratamento de mielofibrose.
MX370253B (es) Composiciones de compuestos de jasmonato y métodos de uso de las mismas.
UY33461A (es) Compuestos heterocíclicos, su preparación y su aplicación terapéutica
WO2012154695A3 (en) Treatment of polycystic disease